Monte Rosa Therapeutics (GLUE) Receivables - Other (2023 - 2025)
Monte Rosa Therapeutics' Receivables - Other history spans 3 years, with the latest figure at $4.6 million for Q4 2025.
- For Q4 2025, Receivables - Other rose 2558.96% year-over-year to $4.6 million; the TTM value through Dec 2025 reached $4.6 million, up 2558.96%, while the annual FY2025 figure was $4.6 million, 2558.96% up from the prior year.
- Receivables - Other reached $4.6 million in Q4 2025 per GLUE's latest filing, down from $5.0 million in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $5.0 million in Q3 2025 to a low of $173000.0 in Q4 2024.
- Average Receivables - Other over 3 years is $1.6 million, with a median of $998000.0 recorded in 2023.
- Peak YoY movement for Receivables - Other: crashed 72.3% in 2024, then soared 2558.96% in 2025.
- A 3-year view of Receivables - Other shows it stood at $505000.0 in 2023, then tumbled by 65.74% to $173000.0 in 2024, then skyrocketed by 2558.96% to $4.6 million in 2025.
- Per Business Quant, the three most recent readings for GLUE's Receivables - Other are $4.6 million (Q4 2025), $5.0 million (Q3 2025), and $2.4 million (Q2 2025).